Loading...
Loading...
KNSA| Name | Value |
|---|---|
| Revenues | 79.9M |
| Cost of Revenue | 31.5M |
| Gross Profit | 48.3M |
| Operating Expense | 64.9M |
| Operating I/L | -16.5M |
| Other Income/Expense | 2.3M |
| Interest Income | 0.0M |
| Pretax | -14.3M |
| Income Tax Expense | 3.4M |
| Net Income/Loss | -17.7M |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic medicines for patients with unmet medical needs. The company's product candidates include ARCALYST for recurrent pericarditis, Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 for the CD40-CD154 interaction. These products target inflammatory cardiovascular diseases, chronic skin conditions, and immune responses. Kiniksa Pharmaceuticals generates revenue through the sale of these innovative medicines to patients worldwide, addressing debilitating diseases and improving patient outcomes.
